Ex vivo-expanded donor CD4(+) lymphocyte infusion against relapsing neuroblastoma: A transient graft-versus-tumor effect.
High-risk neuroblastoma has a poor prognosis despite multimodal treatment including high-dose chemotherapy. A 7-year-old male with neuroblastoma received ex vivo-expanded donor CD4(+) T lymphocyte infusion (CD4(+) DLI) after recurrence in the bone marrow following allogeneic hematopoietic stem cell transplantation from his HLA-identical mother. The disease transiently responded to CD4(+) DLI with reduction of tumor cells and a decrease of serum neuron-specific enolase. The response was associated with development of continued high fever and an increase of cytotoxic T lymphocytes in peripheral blood. This case suggests a possibility of a graft-versus-tumor effect against neuroblastoma.
Yoshida
Hisao
H
Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
Kusuki
Shigenori
S
Hashii
Yoshiko
Y
Ohta
Hideaki
H
Morio
Tomohiro
T
Ozono
Keiichi
K
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D002675:Child, Preschool; D005260:Female; D020350:Graft vs Tumor Effect / Q000502:physiology*; D006680:HLA Antigens / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017710:Lymphocyte Transfusion; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000276:immunology / Q000628:therapy*; D009447:Neuroblastoma / Q000276:immunology / Q000628:therapy*; D010751:Phosphopyruvate Hydratase; D011379:Prognosis; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D016896:Treatment Outcome
D006680:HLA Antigens; D010751:Phosphopyruvate Hydratase